BioSpace News Archive

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its third quarter 2018 financial results and provided an update on the company and its progress with IPI-549, a first-in-class oral immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase-gamma

Tivity Health®, Inc. (NASDAQ:TVTY) today announced financial results for the third quarter ended September 30, 2018

Addus HomeCare Corporation (NASDAQ: ADUS), a provider of home care services, today announced its financial results for the third quarter and nine months ended September 30, 2018.

Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the third quarter ended September 30, 2018.

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended September 30, 2018.

Charles River Associates today announced that Dr. Richard Wenzel, a principal in the Life Sciences Practice at CRA, will present a review of strategies to support more rapid identification and earlier diagnosis of patients living with rare diseases.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented preclinical results that support the potential of CTP-692, the Company’s novel drug candidate for schizophrenia, to improve the safety profile of D-serine. CTP-692 is a deuterated form of D-serine, an endogenous co-agonist of the N-methyl-D-aspartate (NMDA) receptor.

CONMED Corporation today announced that Curt R. Hartman, President and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will present at the Jefferies London Healthcare Conference at 8:40 a.m. GMT (3:40 a.m. ET) on Wednesday, November 14, 2018 in London, UK.

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today provided unaudited financial results for the three and six months ended September 30, 2018.

Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported financial results for the three and nine months ended September 30, 2018.